Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase III KRAS inhibitor candidate, opnurasib, citing an increasingly competitive landscape in the sector. The drug was under development for the treatment of solid tumors, including non-small cell lung cancer (NSCLC).
This decision comes in the wake of early-stage data that indicated anti-tumor activity, with Novartis clarifying that the move was not driven by concerns related to the drug’s efficacy or safety.
In the current market for KRAS inhibitors, Amgen’s (NASDAQ: AMGN) Lumakras (sotorasib) and Bristol Myers Squibb’s (BMS; NYSE: BMY) Krazati (adagrasib) are notable competitors that already have a strong presence.- Flcube.com
